EpiVax Boosts Community Health with GAIA Vaccine Foundation Partnership and Local Initiatives

### EpiVax Strengthens Community Health Initiatives Through Strategic Partnerships

EpiVax, a prominent biotechnology firm based in Providence, R.I., reinforces its commitment to community health by supporting local nonprofits, including Clínica Esperanza/Hope Clinic and the GAIA Vaccine Foundation. Since its establishment in 2010, Clínica Esperanza has provided free healthcare to over 30,000 uninsured patients, primarily serving Spanish-speaking individuals. The clinic's recent initiative, Bridging the Gap (BTG), aims to improve health outcomes specifically for Spanish-speaking immigrants. Featured in the CDC's Preventing Chronic Disease journal, BTG has demonstrated significant progress in managing chronic conditions, particularly diabetes and heart disease, among its participants.

Simultaneously, EpiVax backs the GAIA Vaccine Foundation, which focuses on enhancing infectious disease prevention in underserved populations in West Africa. One of GAIA's noteworthy studies, titled "Our Daughters—Ourselves," reports a 10.7% increase in HPV vaccination rates among out-of-school girls in Bamako, Mali. This innovative approach combines maternal cervical cancer screenings with HPV vaccinations for daughters, reflecting GAIA's dedication to improving women’s health. Building on this success, GAIA plans to expand its efforts into a nationwide HPV vaccination campaign in Mali, further addressing public health challenges in the region.

EpiVax co-founder Dr. Annie De Groot commends the company’s employees for their volunteer work and active engagement with these organizations. Their participation underscores EpiVax's mission to enhance global health through collaborative efforts. The company, which specializes in immunogenicity assessment and vaccine design, continues to play a significant role in supporting these vital health initiatives, demonstrating a strong commitment to improving human health both locally and globally. Through strategic partnerships, donations, and volunteer efforts, EpiVax exemplifies how biotechnology firms can contribute meaningfully to community well-being.

In addition to its philanthropic endeavors, EpiVax actively collaborates with global partners to advance public health initiatives. By focusing on innovative solutions for pressing health issues, EpiVax positions itself as a leader in the biotechnology sector, dedicated to making a tangible impact in communities across the world. The company's commitment to local and global health equity reinforces the critical role that biotechnology can play in addressing healthcare disparities.